• Developed a new blood-based molecular test to evaluate the cardioprotective effects of RC220
• Selected to present on (E,E)-bisantrene's ability to silence MYC gene expression at the 2026 AACR Annual Meeting
• First patient recruited to the Phase 1 HARNESS-1 clinical trial in non-small cell lung cancer patients

Racura Oncology released its Q3 FY2026 report, highlighting significant progress made during the quarter. Key events included the establishment of a collaboration with Emory University to study (E,E)-bisantrene in osimertinib-resistant NSCLC, the development of a new blood-based molecular test to evaluate the cardioprotective effects of RC220, the recruitment of the first patient to the HARNESS-1 Phase 1 clinical trial, and Racura's selection to present on (E,E)-bisantrene's ability to silence MYC gene expression at the 2026 AACR Annual Meeting. Racura also held its inaugural R&D Symposium, providing a detailed overview of the science behind its lead asset (E,E)-bisantrene and its clinical programs. The company maintained a strong cash balance of $19.38 million at the end of the quarter, with more than 81% of spending directed toward R&D and drug manufacturing activities.